266 related articles for article (PubMed ID: 25468044)
21. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
22. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
Patel HM; Pawara R; Ansari A; Noolvi M; Surana S
Bioorg Med Chem; 2017 May; 25(10):2713-2723. PubMed ID: 28366268
[TBL] [Abstract][Full Text] [Related]
24. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
Zhang HQ; Gong FH; Ye JQ; Zhang C; Yue XH; Li CG; Xu YG; Sun LP
Eur J Med Chem; 2017 Jan; 125():245-254. PubMed ID: 27688180
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
El Ella DA; Saleh KA; Hassan M; Hamdy N; El-Araby ME; Abouzid KA
Arzneimittelforschung; 2012 Aug; 62(8):360-6. PubMed ID: 22723174
[TBL] [Abstract][Full Text] [Related]
26. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.
Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F
Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529
[TBL] [Abstract][Full Text] [Related]
28. Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
Ju Y; Wu J; Yuan X; Zhao L; Zhang G; Li C; Qiao R
J Med Chem; 2018 Dec; 61(24):11372-11383. PubMed ID: 30508379
[TBL] [Abstract][Full Text] [Related]
29. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
[TBL] [Abstract][Full Text] [Related]
30. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
[TBL] [Abstract][Full Text] [Related]
31. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.
Barbosa ML; Lima LM; Tesch R; Sant'Anna CM; Totzke F; Kubbutat MH; Schächtele C; Laufer SA; Barreiro EJ
Eur J Med Chem; 2014 Jan; 71():1-14. PubMed ID: 24269511
[TBL] [Abstract][Full Text] [Related]
32. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
[TBL] [Abstract][Full Text] [Related]
33. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
[TBL] [Abstract][Full Text] [Related]
34. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
Ghorab MM; Alsaid MS; Soliman AM; Al-Mishari AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):67-73. PubMed ID: 29098904
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.
Chandregowda V; Kush AK; Chandrasekara Reddy G
Eur J Med Chem; 2009 Jul; 44(7):3046-55. PubMed ID: 18771819
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors.
Zheng YG; Su J; Gao CY; Jiang P; An L; Xue YS; Gao J; Liu Y
Eur J Med Chem; 2017 Apr; 130():393-405. PubMed ID: 28279846
[TBL] [Abstract][Full Text] [Related]
37. Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
Yu H; Li Y; Ge Y; Song Z; Wang C; Huang S; Jin Y; Han X; Zhen Y; Liu K; Zhou Y; Ma X
Eur J Med Chem; 2016 Mar; 110():195-203. PubMed ID: 26829280
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.
Mowafy S; Farag NA; Abouzid KA
Eur J Med Chem; 2013 Mar; 61():132-45. PubMed ID: 23142066
[TBL] [Abstract][Full Text] [Related]
39. 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.
Hamed MM; Abou El Ella DA; Keeton AB; Piazza GA; Abadi AH; Hartmann RW; Engel M
ChemMedChem; 2013 Sep; 8(9):1495-504. PubMed ID: 23847159
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
Hu S; Xie G; Zhang DX; Davis C; Long W; Hu Y; Wang F; Kang X; Tan F; Ding L; Wang Y
Bioorg Med Chem Lett; 2012 Oct; 22(19):6301-5. PubMed ID: 22959248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]